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AbstrACt
Introduction A review of European Union (EU)-funded 
initiatives linked to ‘Real World Evidence’ (RWE) was 
performed to determine whether their outputs could be 
used for the generation of real-world data able to support 
the European Medicines Agency (EMA)’s regulatory 
decision-making on medicines.
Method The initiatives were identified from publicly 
available websites. Their topics were categorised into 
five areas: ‘Data source’, ‘Methodology’, ‘Governance 
model’, ‘Analytical model’ and ‘Infrastructure’. To assess 
their immediate relevance for medicines evaluation, their 
therapeutic areas were compared with the products 
recommended for EU approval in 2016 and those included 
in the EMA pharmaceutical business pipeline.
results Of 171 originally identified EU-funded 
initiatives, 65 were selected based on their primary and 
secondary objectives (35 ‘Data source’ initiatives, 15 
‘Methodology’, 10 ‘Governance model’, 17 ‘Analytical 
model’ and 25 ‘Infrastructure’). These 65 initiatives 
received over 734 million Euros of public funding. At 
the time of evaluation, the published outputs of the 40 
completed initiatives did not always match their original 
objectives. Overall, public information was limited, 
data access was not explicit and their sustainability 
was unclear. The topics matched 8 of 14 therapeutic 
areas of the products recommended for approval in 
2016 and 8 of 15 therapeutic areas in the 2017–2019 
pharmaceutical business pipeline. Haematology, 
gastroenterology or cardiovascular systems were poorly 
represented.
Conclusions This landscape of EU-funded initiatives 
linked to RWE which started before 31 December 
2016 highlighted that the immediate utilisation of 
their outputs to support regulatory decision-making is 
limited, often due to insufficient available information 
and to discrepancies between outputs and objectives. 
Furthermore, the restricted sustainability of the 
initiatives impacts on their downstream utility. Multiple 
projects focussing on the same therapeutic areas 
increase the likelihood of duplication of both efforts and 
resources. These issues contribute to gaps in generating 
RWE for medicines and diminish returns on the public 
funds invested.
IntroduCtIon 
The clinical evidence collected for the 
marketing authorisation of new medi-
cines traditionally comes from randomised 
clinical trials (RCTs) but it is recognised 
that RCT data have limitations including 
tightly controlled conditions of clinical 
care, highly selected populations and, in 
some scenarios, small sample sizes.1 As a 
result, their applicability to the safety and 
efficacy of medicines in postauthorisation 
use is unknown. There is therefore a need 
to supplement RCTs with other sources 
more representative of everyday ‘real world’ 
strengths and limitations of this study
 ► This is the first comprehensive  evaluation of 
European Union-funded initiatives linked to ‘Real 
World Evidence’ that looks at their  usefulness to 
support regulatory decision-making on medicines.
 ► The analysis is based on review of the publicly avail-
able information provided by each initiative on their 
English language websites.
 ► The internet search was based on a list of inter-
nally agreed keywords which might not be fully 
exhaustive.
 ► The follow-up period to perform the second and 
third steps of our analysis was 6 months (January to 
June 2017). This might not have been long enough 
to cover the time lag between the finalisation of 
some of the initiatives and the publication of their fi-
nal reports, and therefore our analysis may not have 
taken into account their final outputs.
 ► The website of each initiative was reviewed by indi-
vidual European Medicines Agency  staff members. 
However, in some cases, there were (1) limited infor-
mation published on the websites, (2) broken links 
and (3) both limited access/limited information on 
access to data, which made it difficult to determine 
the appropriateness of the initiatives’ attributes for 
inclusion in the inventory, and conclude on their gen-
eral applicability to regulatory science.
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medical practice in order to provide additional insight 
on the benefit–risk balance.
According to the GetReal Glossary of Definitions of 
Common Terms,2 ‘Real World Evidence’ (RWE) derives 
from the analysis and/or synthesis of ‘Real World Data’ 
(RWD) that can either be primary data collected in a 
manner which reflects how interventions would be used 
in routine clinical practice or secondary data derived from 
routinely collected data. The range of RWD is wide and 
sources include electronic healthcare records, patient/
disease registries, hospital records and health insurance 
data/claims databases. The EU Network Strategy to 2020 
identifies RWE as a key enabler to bring innovative prod-
ucts to patients with unmet medical needs and to support 
the safe and effective use of medicines.3
While the European Medicines Agency (EMA) 
already uses RWE sources in its evaluations, this is typi-
cally on an ‘ad hoc’ basis. There is therefore a need to 
systematically understand RWE outputs at an European 
Union (EU)-wide level in order to make best use of 
existing information and to identify areas where further 
efforts are needed. We created an inventory of EU-funded 
initiatives linked to RWE and RWD. The objectives were: 
(1) to identify the initiatives established in terms of RWD 
sources, relevant methodologies, governance models, 
analytical models and infrastructures created to facilitate 
RWD collection, transformation, sharing and analysis; 
(2) to understand if and how these initiatives could be 
exploited to support regulatory decision-making on medi-
cines4 ; and (3) to consider the initiatives strategically in 
terms of needs, gaps and opportunities for the genera-
tion of RWD related to the therapeutic areas of medicinal 
products in the pharmaceutical development pipeline.
Methods
selection (first step)
A three-step approach was followed (figure 1), starting 
with an internet search performed by one reviewer (KP) 
to identify completed and ongoing RWE initiatives funded 
through the sixth and seventh Framework Programmes 
(FP6/FP7),5 6 Horizon 2020 (H2020)7 (including the Inno-
vative Medicines Initiative (IMI)8), other EU initiatives (eg, 
European Research Council, Strengthening Collaboration 
for Operating Pharmacovigilance in Europe Joint Action,9 
HIMSS Europe Governing Council10) and nationally 
funded initiatives discovered during the search. The search 
terms used were: registry/ies, real world evidence, clinical, 
electronic medical record, eHealth, big data, electronic 
health record, data linkage/link, paediatrics, pregnancy, 
geriatrics, hospital data, data source, unique patient iden-
tifier, coding terminology, governance model, common 
protocol, distributed data approach, pooling of data and 
analytical model. The search cut-off date was 31 December 
2016; as such, all initiatives identified via the search terms 
which began before or on that date and were funded by 
either the EU or national bodies were included.
Initiatives started on or before this date that matched any 
of the keywords were included in an Excel tracking table 
(see online supplementary file, section 1.1). Based on their 
website information, they were categorised according to 
the development of potentially relevant (1) RWD sources, 
(2) methodologies, (3) governance models, (4) analyt-
ical models or (5) infrastructure that could help provide 
evidence to support regulatory decision-making (see online 
supplementary file, section 1.2.1). Initiatives could fall into 
more than one category. Those that did not focus on one 
Figure 1 Development steps of the inventory of European Union-funded ‘Real World Evidence’ initiatives.
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or more of the categories or that focused only on the early 
stage of drug development (eg, preclinical or clinical trials, 
development of molecular compounds/biomarkers), on 
the ‘-omics’ (eg, genomics) or on diseases with limited 
geographical spread (eg, Ebola outbreak) (figure 2) were 
considered out of scope of the inventory and were there-
fore not selected for further analysis.
Category attributes (second step)
For each of the five categories, attributes were defined 
to facilitate selection of the outputs potentially most rele-
vant for assisting in regulatory evaluations (eg for data 
sources, the attributes included access, database linkage, 
unique patent identifier or paediatrics data). Three 
reviewers (KP, PM, AP) with experience in pharmacovig-
ilance and regulatory science identified the primary and 
secondary objectives of the initiatives, their attributes 
and their corresponding deliverables through examina-
tion of the initiatives’ webpages and review of published 
documents including reports, presentations and publica-
tions. They then assigned the initiatives to one or more 
categories as appropriate (see online supplementary 
file, sections 1.1 and 1.2.2). In cases of doubt, the three 
reviewers met face-to-face to achieve consensus.
scoring (third step)
A dashboard listing all the attributes was created for each 
category. Each initiative was categorised and characterised 
through identification and scoring of its attributes. Scores 
ranged from 0 to 2 for ‘Yes/No’ questions, for example, 
on whether the data source included paediatric data 
(where 0=‘No’, 1=‘Unknown’ and 2=‘Yes’), or from 0 to 3 
for more qualitative questions, for example, on the type of 
care covered (0=‘Unknown’, 1=‘Primary’, 2=‘Secondary/
Tertiary’ and 3=‘Primary, Secondary, Tertiary’).
Two attributes were scored across all dashboards: (1) 
the availability of published outputs at the end of each 
completed project, and (2) whether the published 
outputs fully addressed the originally stated objectives. 
The dashboards permitted the creation of graphs for 
each of the categories showing the number of initiatives 
fulfilling each attribute according to the information 
provided on their websites.
Initiative partners and funding
The numbers of partners named in each initiative and 
the amount of funding awarded were included in each 
dashboard.
therapeutic areas of the initiatives, new medicinal products 
and eMA business pipeline
The therapeutic areas of the initiatives included in the 
data source category were mapped to:
 ► Those of the products recommended for approval 
through the EU centralised authorisation procedure 
by the Committee for Medicinal Products for Human 
Use11 in 2016.
 ► Those of the products included in the EMA pharma-
ceutical business pipeline12 through which developers 
have expressed a clear intent to submit a marketing 
authorisation application (MAA) through the central-
ised procedure to the EMA between March 2017 and 
December 2019.
Patient involvement statement
This descriptive analysis did not involve any patients.
results
The first screening returned 171 potentially relevant 
initiatives (see online supplementary file, section 1.1) that 
matched at least one of the search keywords. Following 
the second screening, 115 initiatives were reviewed for 
categorisation (51 FP, 30 IMI, 15 H2020, 12 other EU 
initiatives, 7 nationally funded initiatives), of which 65 fell 
into one or more of the five categories (figure 2). Some 
initiatives were included in more than one category, 
for example, data source initiatives that also developed 
Figure 2 Selections of initiatives for the inventory of European Union-funded ‘Real World Evidence’ initiatives.
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infrastructure. The selected initiatives had a median 
duration of 5 years.
dashboards scoring and summary of findings
Initiatives were scored in the dashboards according to 
their category(ies) attributes. The main findings for 
each category are summarised below and illustrated 
in figure 3. The scoring dashboards are provided in 
the online supplementary file, section  2.1.
 ► Data sources: Information on access to the data 
sources developed through the initiative was available 
on the websites of 5 of the 35 data source initiatives, 
including two where only the data custodian had 
access, and three where access was open to collabora-
tors. Access information was either not publicly avail-
able or unclear for the remaining 30 initiatives.
 ► Methodologies: 15 initiatives developed methodolo-
gies that could be applied to RWD studies, including 
guidance on protocol design (9), on the management 
of bias/confounders (5) and on the use of electronic 
health records and/or registry data (6). Seven initi-
atives referred to the use of established diseases or 
drug coding terminologies such as MedDRA, Snomed 
CT, ATC or Orphanet.
 ► Governance models: 10 initiatives dealt with confiden-
tiality and data protection aspects, while six related to 
a new code of conduct.
 ► Analytical models: 10 of 17 initiatives aimed to develop 
smart text analysis tools such as machine learning, 
natural language programming or data mining. Data 
transformation (anonymisation, privacy and compres-
sion) was referred to in nine initiatives.
 ► Infrastructure: All 25 initiatives related to the devel-
opment of platforms or websites to share, extract and 
store data, of which two also mentioned cloud-based 
technologies. Three developed a smartphone appli-
cation that could be used by stakeholders including 
patients to record personal health information or 
report suspected adverse drug reactions.
outputs versus objectives
The outputs matched the objectives for all 5 of the 
completed ‘Governance model’ initiatives (100%), 5 of the 
6 completed ‘Methodology’ initiatives (83%), 10 of the 12 
completed ‘Infrastructure’ initiatives (83%), 15 of the 23 
completed ‘Data source’ initiatives (65%) and for 7 of the 
12 completed ‘Analytical model’ initiatives (58%) (table 1).
Initiatives’ sustainability
While some initiatives continued beyond their agreed 
timelines through new EU-funded programmes within, 
for example, H2020, or were followed up by existing 
networks (eg, foundations, associations), others ceased 
at the end of their allocated time and budget without a 
sustainability plan for any of the outputs delivered. Of 
the 23 completed ‘Data source’ initiatives, 7 had a clear 
sustainability mechanism described on their website, for 
example, the European Medical Information Frame-
work Project.13 Some more recent initiatives integrate 
roadmaps for future development and continuation as 
part of their deliverables, like RETHINK big.14
Comparison of therapeutic areas
Of the 14 different therapeutic areas where products 
were recommended by the EMA for approval in 2016 
Figure 3 Attributes of the European Union (EU)-
funded initiatives according to each of the five 
categories. EHR, electronic health record; RW, real world.
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and of the 15 represented in the EMA business pipe-
line, 8 were studied by the initiatives (figures 4 and 5). 
These included oncology (five initiatives), neurology/
central nervous system (CNS) (seven), respiratory 
(five), immunology (five), rheumatology (three) and 
metabolic diseases (two). Other therapeutic areas 
where new products were about to be approved or 
MAAs submitted were not represented in the initiatives, 
including in particular haematology, gastroenterology 
or cardiovascular system.
number of partners and funding
Information on funding was available on the websites 
of 53 of the 65 initiatives categorised and scored. The 
total funding was 734 million Euros ranging from 1 to 
56 million Euros. Information on the numbers of part-
ners was provided for 58 initiatives and ranged from 1 to 
161 partners.
For large initiatives (>20 partners), there was no clear 
relation between the number of partners and the amount 
of funding (figure 6, funding of the 30 ‘Data source’ 
initiatives). The same partners were involved in multiple 
initiatives, especially pharmaceutical companies as well as 
academic centres.
dIsCussIon
To our knowledge, this is the first evaluation of EU-funded 
initiatives in terms of their potential to develop RWD 
sources, methodologies, governance models, analytical 
models or infrastructure to contribute to the utility of 
RWE. It highlights discrepancies between the objectives 
of the identified initiatives and their outputs, a lack of 
sustainability of the outputs and a mismatch with the 
therapeutic areas of drugs recently recommended for 
approval by the EMA and appearing in its business pipe-
line. Nevertheless, the inventory will be useful for the 
EMA on receipt of enquiries arising in the course of regu-
latory assessments of medicinal products as the five dash-
boards and the relevant attributes may provide sources of 
additional evidence to support decision-making.
observation
Of 35 ‘Data source’ initiatives, 27 developed RWD 
sources that focused on diseases in eight specific thera-
peutic areas, more than the half of which (17) clustered 
in neurology/CNS, oncology and respiratory (figures 4 
and 5). These multiple parallel initiatives with a substan-
tial number of partners sometimes involved in the same 
projects may increase the risk of (1) duplication of 
efforts and resources, (2) overlap of final outputs and (3) 
Table 1 Number of completed initiatives with outputs matching objectives
Categories (number of initiatives) Initiatives completed/ongoing Outputs matched objectives Unclear if outputs matched objectives
Data source (n=35) 23/12 15 (65%) 8 (35%)
Methodology (n=15)  6/9 5 (83%) 1 (17%)
Governance model (n=10)  5/5 5 (100%) 0
Analytical model (n=17) 12/5 7 (58%) 5 (42%)
Infrastructure (n=25) 12/13 10 (83%) 2 (17%)
Figure 4 Specific therapeutic areas of products recommended for approval in 2016 versus those covered by the identified 
initiatives. CNS, central nervous system; RW, real world.
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generation of unsustainable and non-interoperable data 
sources. Most initiatives consisted of standalone projects, 
and while a handful provided a clear set of definitions, 
most provided no apparent plan to enable the delivery of 
a sustainable platform on, for example, future data gener-
ation, access and reuse. This may result from an omission 
of the funding bodies to request such a plan or from 
the lack of incentives, for example, the lack of ongoing 
funding options.
The inventory highlights that some areas of new 
product development such as haematology, gastroenter-
ology and cardiovascular system are not represented in 
the RWD sources identified in the inventory. Therefore, 
opportunities to generate RWD to support evaluation 
and decision-making on new products could be created 
through new initiatives targeting these therapeutic 
areas. It is possible that such omissions will be addressed 
to some extent by the strategic research agenda of the 
Figure 5 Specific therapeutic areas of products included in the European Medicines Agency business pipeline (March 2017 to 
December 2019) versus those covered by the identified initiatives. CNS, central nervous system; RW, real world. 
Figure 6 Number of partners versus funding of ‘Data source’ initiatives.
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recently launched IMI 215 (eg, Big Data for Better 
Outcomes Programme16).
While the inventory focuses on EU-funded initiatives, 
the same exercise could be extended to international 
initiatives in order to enlarge the geographical spread and 
number of data sources, provide a better understanding 
of populations studied in real world settings worldwide 
and widen the possibility of linkage between data sources 
through new analytical models.
limitations
The three consecutive steps were based on the review 
of the English version of the websites by individual 
EMA staff members. The internet search was based 
on an agreed list of keywords which might not have 
been fully exhaustive and therefore some relevant 
initiatives may be missing. The follow-up period to 
perform the second and third steps of our analysis was 
only 6 months (January to June 2017), and therefore 
does not take into account any final outcomes of the 
originally identified initiatives that were published 
afterwards. However, in general, limited information 
published on the websites (eg, lack of final reports or 
accounts of deliverables while some initiatives did not 
even have a website), broken links and both limited 
access/limited information on access to the data made 
it sometimes difficult to determine the initiatives’ 
attributes for inclusion in the inventory, let alone 
conclude on their general applicability to regulatory 
science. As the initiatives were publicly funded, it is 
reasonable to expect that their websites would provide 
up-to-date information including published outputs 
as well as some indication in relation to mechanisms 
of data access and sustainability. Adoption of the 
suggestion of Galsworthy et al to develop a central EU 
repository to make outputs permanently accessible for 
open meta-analysis and data reuse could improve this 
shortcoming.17 18 For initiatives whose data contribute 
to postauthorisation studies, their registration in the 
publicly accessible EU PAS Register provides an oppor-
tunity to increase the dissemination of methods and 
results.19
Proposed way forward
From our review, there is an apparent lack of an over-
arching vision for an infrastructure that would provide 
sustainable access to the data generated by the projects. 
Having said that, most recent initiatives include roadmaps 
as part of their deliverables which may potentially assist in 
delivering sustainability in the future. Moreover, the 11th 
Call for Proposals launched by the IMI 2 Joint Under-
taking20 aims to provide solutions to ensure that signifi-
cant results from IMI projects become fully exploitable, 
available to all relevant end users and/or fully sustainable 
in the long term and in their own right.
Based on our analysis, we highlight the following addi-
tional options that stakeholders including the Euro-
pean Commission, regulators, academia, sponsors and 
advocacy groups may wish to consider for ensuring better 
exploitation of funded initiatives:
 ► Regulators and relevant end-users of the final deliver-
ables should be involved early on in the planning and 
definition of the EU-funded initiatives.
 ► To streamline efforts and resources and promote 
interoperability between outputs, consideration 
should be given to existing data and lessons learnt 
from past projects. This should help the identification 
of the real public health needs to be addressed by new 
initiatives.
 ► If timescales allow, future EU RWE initiatives could 
take account of the EMA business pipeline on medic-
inal products to avoid gaps in the generation of RWD 
and ensure regulatory needs are supported.
 ► Consideration should be given to the development of 
an agreed set of common data elements across data 
sources to promote harmonisation and interoper-
ability, especially across those focused on the same 
therapeutic areas.
 ► Use of real world data to support regulatory deci-
sion-making requires an in-depth understanding of 
the capture, characteristics, quality and validity of the 
data. Better quantification and information on these 
areas would enhance utility in the regulatory setting, 
for example, through the use of the available EMA 
procedure on qualification of novel methodologies 
for medicine development.21
 ► The maintenance of the initiatives’ websites at the end 
of the funding period is key to ensure stakeholders are 
able to keep up to date on the progress made and on 
the deliverables/achievements. Maintenance of these 
websites should permit easy public access to informa-
tion, related reports and peer-reviewed publications 
but would require dedicated funding.
 ► There is a need for clarity on the possibilities to access 
RWD sources generated by the initiatives to allow 
their reuse in other contexts.
 ► Consideration of explicit mechanisms to ensure 
the sustainability of outputs delivered by initiatives 
should be a priority and should be a requirement 
for any project proposal. The availability of funding 
options to support the ongoing maintenance of RWD 
resources would incentivise their development and 
ensure as wide an access as possible.
ConClusIon
This inventory provides a better understanding of the 
extent of existing RWD resources emerging from 
EU-funded initiatives and highlights multiple shortcom-
ings. Ideally, results of such initiatives should be reused 
and sustained and any lessons learnt disseminated. 
However, despite the potential of some initiatives to 
provide RWE that would support decision-making on 
the safety of medicinal products, there are challenges for 
their utilisation in a regulatory context due to the obsta-
cles in the exploitation of their outputs (eg, limited data 
access, lack of sustainability).
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Gaps and opportunities were identified in terms of 
specific therapeutic areas which may require RWD but 
were not a focus of funded initiatives. A number of 
solutions are proposed to enable better streamlining, 
communication and sustainability of the outputs gener-
ated through the EU-funded initiatives. As the 65 initia-
tives together were granted more than 734 million 
Euros of public funding, it is imperative that the short-
comings highlighted here are addressed in future 
funding programmes. This would go some way to 
ensuring delivery of stated objectives, data availability, 
sustainability and reflection of areas of medical need.
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